Skip to main content
SpringerLink
Log in

Strategies for Colon Cancer Prevention

Combination of chemopreventive agents

  • Chapter
Book cover Inflammation in the Pathogenesis of Chronic Diseases

Part of the book series: Subcellular Biochemistry ((SCBI,volume 42))

Abstract

Large bowel cancer is one of the most common human malignancies in western countries, including North America. Several epidemiological studies have detected decreases in the risk of colorectal cancer in individuals who regularly use aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical trials with NSAIDs in patients with familial adenomatous polyposis have demonstrated that treatment with NSAIDs causes regression of pre-existing adenomas. Preclinical efficacy studies using realistic laboratory animal models have provided scientifically sound evidence as to how NSAIDs act to retard, block, and reverse colonic carcinogenesis. Selective COX-2 inhibitors (celecoxib) as well as naturally occurring anti-inflammatory agents (curcumin) have proven to be effective chemopreventive agents against colonic carcinogenesis. There is growing optimism for the view that realization of preventive concepts in large bowel cancer will also serve as a model for preventing malignancies of the prostate, the breast, and many other types of cancer. There is increasing interest in the use of combinations of low doses of chemopreventive agents that differ in their modes of action in order to increase their efficacy and minimize toxicity. Preclinical studies conducted in our laboratory provide strong evidence that the administration of combinations of chemopreventive agents (NSAIDs, COX-2 inhibitors, DFMO, statins) at low dosages inhibit carcinogenesis more effectively and with less toxicity than when these agents are given alone

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jamal A, Murray T, Ward E, Samuels A, et al: Cancer Statistics. CA Cancer J Clin 2005, 55: 10–30.

    Article  Google Scholar 

  2. World Cancer Research Fund and American Institute for Cancer Research, Panel on Food, Nutrition and Prevention. Washington DC: American Institute for Cancer Research 1997.

    Google Scholar 

  3. Potter JD, Steinmetz K. In: Principles of Chemoprevention. (Steward BW, McGregor D, Kleihues P. eds). IARC Scientific Publication No. 139. International Agency for Research on Cancer, Lyon, France. 1996: 61–90.

    Google Scholar 

  4. Wattenberg L. Inhibition of tumorigenesis in animals. In: Principles of Chemoprevention (Stewart BW, McGregor D, Kleihues P. eds). IARC Scientific Publication No. 199, International Agency for Research on Cancer, Lyon, France. 1996: 151–158.

    Google Scholar 

  5. Kelloff GJ. Perspectives on cancer prevention research and drug development. Adv Cancer Res 2000, 78: 1999–2334.

    Google Scholar 

  6. Reddy BS, Rao CV. Chemoprophylaxis of Colon Cancer. Current Gastroenterology Reports 2005, 7( 5):389–395.

    PubMed  Google Scholar 

  7. Coussens LM, Werb Z. Inflammation and Cancer. Nature 2002, 420:56–867.

    Article  CAS  Google Scholar 

  8. Balkwill F, Mantovani A. Inflammation and Cancer. Lancet 2001, 357:539–545.

    Article  PubMed  CAS  Google Scholar 

  9. Thun MJ, Namboodiri MM, Heath CJ Jr. Aspirin Use and Reduced Risk of Fatal Colon Cancer. N. Engl. J. Med. 1991, 325:1593–1596.

    Article  PubMed  CAS  Google Scholar 

  10. Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin Use and Risk of Fatal Cancer. Cancer Res. 1993, 53:1322–1327.

    PubMed  CAS  Google Scholar 

  11. Giovannucci E, Rimm EB, Stampfer M, et al. Aspirin Use and Risk for Colorectal Cancer and Adenoma in Male Health Professionals. Ann. Intern. Med. 1994, 121:241–246.

    PubMed  CAS  Google Scholar 

  12. Kune G, Kune S, Watson LF. Colorectal Cancer Risk, Chronic Illnesses, Operations, and Medications: Case Control Results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988, 48:4399–4404.

    PubMed  CAS  Google Scholar 

  13. Reddy BS. Carcinogen-induced colon cancer models for chemoprevention and nutritional studies in: tumor models in Cancer Research. (ed., Teicher BA). Human Press, Totowa, NJ 2002, 183–191.

    Google Scholar 

  14. Narisawa T, Sato M, Tani M, et al. Inhibition of Development of Methylnitrosourea-Induced Rat Colon Tumors by Indomethacin Treatment. Cancer Res. 1981, 41:1954–1957.

    PubMed  CAS  Google Scholar 

  15. Narisawa T, Sato M, Sano M, Takahashi T. Inhibition of Development of Methylnitrosourea-Induced Rat Colonic Tumors by Peroral Administration of Indomethacin. Gann. 1982, 73:377–381.

    PubMed  CAS  Google Scholar 

  16. Pollard M, Luckert PH. Prolonged Anti-tumor Effect of Indomethacin on Autochthonous Intestinal Tumors in Rats. J. Natl. Cancer Inst. 1983, 70:1103–1105.

    PubMed  CAS  Google Scholar 

  17. Reddy BS, Maruyama H, Kelloff G. Dose-Related Inhibition of colon Carcinogenesis by Dietary Piroxicam, A Nonsteroidal Anti-inflammatory Drug, During Different Stages of Rat Colon Tumor Development. Cancer Res. 1987, 47:5340–5346.

    PubMed  CAS  Google Scholar 

  18. Reddy BS, Tokumo K, Kulkarni N, et al. Inhibition of Colon Carcinogenesis by Prostaglandin Synthesis Inhibitors and Related Compounds. Carcinogenesis 1992, 13:1019–1023.

    Article  PubMed  CAS  Google Scholar 

  19. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory Effect of Aspirin on Azoxymethane-Induced Colon Carcinogenesis in F 344 Rats. Carcinogenesis 1993, 14:1493–1497.

    Article  PubMed  CAS  Google Scholar 

  20. Moorghen M, Ince P, Finney KJ, et al. The Effect of Sulindac on Colonic Tumor Formation in Dimethylhydrazine-Treated Mice. Acta. Histochem. Suppl. 1990, 39:195–199.

    PubMed  CAS  Google Scholar 

  21. Skinner SA, Penney AG, O’Brien P. Sulindac Inhibits the Rate of Growth and Appearance of Colon Tumors in the Rat. Arch. Surg. 1991, 126:1094–1096.

    PubMed  CAS  Google Scholar 

  22. Reddy BS, Kawamori T, Lubet RA, et al. Chemopreventive Efficacy of Sulindac sulfone Against Colon Cancer Depends on Time of Administration During Carcinogenic Process. Cancer Res. 1999, 59:3387–3391.

    PubMed  CAS  Google Scholar 

  23. Wargovich MJ, Chen CD, Harris C, et al. Inhibition of Aberrant Crypt Growth by Non-Steroidal Anti-Inflammatory Agents and Differentiation Agents in the Rat Colon. Int. J. Cancer. 1995, 60:515–519.

    Article  PubMed  CAS  Google Scholar 

  24. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 Overexpression and Tumor Formation are Blocked by Sulindac in A Murine Model of Familial Adenomatous Polyposis. Cancer Res. 1996, 56:2556–2560.

    PubMed  CAS  Google Scholar 

  25. Chiu CH, Mcentee MF, Whelan J. Sulindac Causes Rapid Regression of Preexisting Tumors in Min/+ Mice Independent of Prostaglandin Biosynthesis. Cancer Res. 1997, 57:4267–4273.

    PubMed  CAS  Google Scholar 

  26. Mahmoud NN, Dannenberg AJ, Mestre J, et al. Aspirin Prevents Tumors in a Murine Model of Familial Adenomatous Polyposis. Surgery 1998, 124:225–231.

    PubMed  CAS  Google Scholar 

  27. Dubois RN, Tsujii M, Bishop P, Awad JA, Makita K, Lanaham A. Cloning and characterization of growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am J Physiol. 1994, 266( 5 Pt 1):G822–G827.

    PubMed  CAS  Google Scholar 

  28. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, Dubois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005, 23:254–266.

    Article  PubMed  CAS  Google Scholar 

  29. Oshima M, Murai N, Kargman S, et al. Chemoprevention of Intestinal Polyposis in the APC Δ716 Mouse by Rofecoxib, A Specific Cyclooxygenase-2 Inhibitor. Cancer Res. 2001, 61: 1733–1740.

    PubMed  CAS  Google Scholar 

  30. Reddy BS, Rao CV. Colon cancers: a role for cyclooxygenase-2 specific non-steroidal anti-inflammatory drugs. Drugs & Aging 2000, 16:329–334.

    Article  CAS  Google Scholar 

  31. Jacoby RF, Seibert K, Cole CF, et al. The Cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res. 2000, 60:5040–5044.

    PubMed  CAS  Google Scholar 

  32. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive Activity of Celecoxib, A Specific Cyclooxygenase-2 Inhibitor, Against Colon Carcinogenesis. Cancer Res. 1998, 58:409–412.

    PubMed  CAS  Google Scholar 

  33. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of Colon Cancer by Specific Cyclooxygenase-2 Inhibitor, Celecoxib, Administered During Different Stages of Carcinogenesis. Cancer Res. 2000, 60:293–297.

    PubMed  CAS  Google Scholar 

  34. Cooma I, Malisetty VS, Patlolla JM, et al. Chemoprevention of Colon Carcinogenesis by Oleanolic Acid and Its Analog in Male F 344 Rats and Modulation of Inos and COX-2, and Apoptosis in Human Colon Ht-29 Cancer Cells. Am. Assoc. For Cancer Res. 2002, 40:819.

    Google Scholar 

  35. Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of Colon Carcinogenesis by Dietary Curcumin, A Naturally Occurring Plant Phenolic Compound. Cancer Res. 1995, 55:259–266.

    PubMed  CAS  Google Scholar 

  36. Kawamori T, Lubet R, Steele VE, et al. Chemopreventive Effect of Curcumin, A Naturally-Occurring Anti-inflammatory Agent, During the Promotion/Progression Stages of colon Cancer. Cancer Res. 1999, 59:597–601.

    PubMed  CAS  Google Scholar 

  37. Rao CV, Simi B, Reddy BS. Inhibition by Dietary Curcumin of Azoxymethane-Induced Ornithine Decarboxylase, Tyrosine Protein Kinase, Arachidonic Acid Metabolism and Aberrant Crypt Foci in the Rat Colon.Carcinogenesis 1993, 14:2219–2225.

    Article  PubMed  CAS  Google Scholar 

  38. Rao CV, Desai D, Rivenson A, Simi B, et al. Chemoprevention of Colon Carcinogenesis by Phenlethyl-3-Methylcaffeate. Cancer Res. 1995, 55:2310–2315.

    PubMed  CAS  Google Scholar 

  39. Rao CV, Desai D, Simi B, et al. Inhibitory Effects of Caffeic Acid Esters on Azoxymethane-Induced Biochemical Changes and Aberrant Crypt Foci Formation in Rat Colon. Cancer Res. 1993, 53:4182–4188.

    PubMed  CAS  Google Scholar 

  40. Huang MT, Ma W, Yen P, et al. Inhibitory Effects of Caffeic Acid Phenethyl Ester (CAPE) on 12-O-Tetradecanoylphorbol-13-Acetate-Induced Tumor Promotion in Mouse Skin and the Synthesis of DNA, RNA and Protein in Hela Cells. Carcinogenesis 1996, 17:761–765.

    Article  PubMed  CAS  Google Scholar 

  41. Mahmoud NN, Carothers AM, Grunberger D, et al. Plant Phenolics Decrease Intestinal Tumors in an Animal Model of Familial Adenomatous Polyposis. Carcinogenesis 2000, 21:921–927.

    Article  PubMed  CAS  Google Scholar 

  42. Xu YX, Pindolia KR, Janakiraman N, et al. Curcumin Inhibits 1L-1 α and TNF- α Induction of AP-1 and NF- κ B DNA-Binding Activity in Bone Marrow Stromal Cells. Hematophathol. Mol. Hematol 1998, 11:49–62.

    CAS  Google Scholar 

  43. Taylor JD. Lipoxygenase Regulation of Membrane Expression of Tumor Cell Glycoproteins and Subsequent Metastasis. Adv. Prostaglandin Thromboxane Leukot. Res. 1989, 19:439–443.

    PubMed  Google Scholar 

  44. Natarajan K, Singh S, Burke TR Jr, et al. Caffeic Acid Phenethyl Ester is a Potent and Specific Inhibitor of Activation of Nuclear Transcription Factor N f -Kappa B. 1996, 93:9090–9095.

    CAS  Google Scholar 

  45. Reddy BS, Nayani J, Tokumo K, et al. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a non-steroidal anti-inflammatory drug with D, L- α -difluoromethy-ornithine. An ornithine decarboxylase inhibitor, in diet. Cancer Res. 1990, 50:2562–2568.

    PubMed  CAS  Google Scholar 

  46. Van der donk NWCI, Kamphuis MMJ, Lokhorst HM, Bloem AC. The choesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002, 16:1362–1371.

    Article  PubMed  CAS  Google Scholar 

  47. Cuthbert JA, Lipsky PE. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism. Cancer Res. 1997, 57:3498–3505.

    PubMed  CAS  Google Scholar 

  48. Demierre M-F, Higgins PDR, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005, 5:930–942.

    Article  PubMed  CAS  Google Scholar 

  49. Agarwal B, Rao CV, Bhendwal S, et al. Lovastatin Augments Sulindac-Induced Apoptosis in Colon Cancer Cells and Potentiates Chemopreventive Effect of Sulindac. Gastroenterology 1999, 117:838–847.

    Article  PubMed  CAS  Google Scholar 

  50. Malisetty VS, Cooma I, Reddy BS, et al. Caspase-3-Activity, and Apoptosis Induction by a Combination of HMG-Coa Reductase Inhibitor and COX-2 Inhibitors: A Novel Approach in Developing Effective Chemopreventive Regimens. Int. J. Oncol. 2002, 20:753–759.

    Google Scholar 

  51. Reddy BS, Wang CX, Kong A-N, et al. Prevention of Azoxymethane-Induced Colon Cancer by Combination of Low Doses of Atorvastatin, Aspirin, and Celecoxib in F 344 Rats. Cancer Res. 2006, 66(8):4542–4546.

    Article  PubMed  CAS  Google Scholar 

  52. Reddy BS, Patlolla JM, Simi B, et al. Prevention of Colon Cancer by Low Doses of Celecoxib, a Cyclooxygenase as Inhibitor, Administered in Diet Rich in ω -3 Polyunsaturated Fatty Acids. Cancer Res. 2005, 65(17):8022–8027.

    PubMed  CAS  Google Scholar 

  53. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis. N. Engl. J. Med. 1993, 328:1313–1316.

    Article  PubMed  CAS  Google Scholar 

  54. Labayle D, Fischer D, Vielh P, et al. Sulindac Causes Regression of Rectal Polyps in Familial Adenomatous Polyposis. Gastroenterology 1991, 101:635–639.

    PubMed  CAS  Google Scholar 

  55. Lynch HT, Thorson AG, Smyrk T. Rectal Cancer after Prolonged Sulindac Chemoprevention. A Case Report. Cancer 1995, 75:936–938.

    Article  PubMed  CAS  Google Scholar 

  56. Tonelli F, Valanzano R. Sulindac in Familial Adenomatous Polyposis. Lancet 1993, 342:1120.

    Article  PubMed  CAS  Google Scholar 

  57. Ladenheim J, Garcia G, Titzer D, et al. Effect of Sulindac on Sporadic Colonic Polyps. Gastroenterology 1995, 108:1083–1087.

    Article  PubMed  CAS  Google Scholar 

  58. Lao CD, Riffin MT, Normalle D, et al. Dose escalation of curcuminoid formulation. BMC Complimentary and Alternative Medicine. 2006, 6:10.

    Article  CAS  Google Scholar 

  59. Bertagnolli MM, Eagle CJ, Hawk ET. Celecoxib reduces sporadic colorectal adenomas: results from adenoma prevention with celecoxib (APC) trial. Proceedings of American Association for Cancer Research. 2006; Abstract CP 3.

    Google Scholar 

  60. Arber N, Racz I, Spicak J, et al. Chemoprevention of colorectal adenomas with celecoxib in an international randomized, placebo-controlled, double-blind trials. Proceedings of American Association for Cancer Research. 2006; Abstract CP 4.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Susan Lehman Cullman Laboratory for Cancer Research, American Health Foundation, Valhalla, New York, U.S.A

    Bandaru S. Reddy

Authors
  1. Bandaru S. Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center of Molecular Epidemiology and Environmental Health, College of Medicine and School of Public Health, The Ohio State University Medical Center, Columbus, Ohio, USA

    Randall E. Harris (Director) (Director)

  2. Queens College, City University of New York, New York, USA

    R. Bittman

  3. Saha Institute of Nuclear Physics, Calcutta, India

    D. Dasgupta

  4. Max-Planck-Institute for Biochemistry, Munich, Germany

    H. Engelhardt

  5. MOLISA GmbH, Magdeburg, Germany

    L. Flohe

  6. German Cancer Research Center, Heidelberg, Germany

    H. Herrmann

  7. Texas A&M University, Texas, USA

    A. Holzenburg

  8. National University of Ireland, Galway, Ireland

    H-P. Nasheuer

  9. The Hebrew University, Jerusalem, Israel

    S. Rottem

  10. DSM Nutritional Products Ltd., Basel, Switzerland

    M. Wyss

  11. Max-Planck-Institute for Biochemistry, Munich, Germany

    P. Zwickl

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer

About this chapter

Cite this chapter

Reddy, B.S. (2007). Strategies for Colon Cancer Prevention. In: Harris, R.E., et al. Inflammation in the Pathogenesis of Chronic Diseases. Subcellular Biochemistry, vol 42. Springer, Dordrecht. https://doi.org/10.1007/1-4020-5688-5_10

Download citation

Publish with us

Policies and ethics

Search

Navigation